ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "f473a46a-2814-466e-927f-de0d42a6c1ca"}, "_deposit": {"created_by": 1, "id": "76134", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "76134"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00076134", "sets": ["29"]}, "author_link": ["765073", "765065", "765066", "765079", "765071", "765068", "765074", "765067", "765072", "765070", "765069", "765078", "765077", "765075", "765080", "765076"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2019-06-24", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: Pancreatic cancer has a very poor prognosis. Surgery is the primary treatment for patients with resectable pancreatic cancer; however, local recurrence, hepatic metastasis, and peritoneal dissemination often occur even after extensive surgery. Adjuvant chemotherapy, typically with gemcitabine, has been used clinically, but with a modest survival benefit. To achieve a better outcome, we investigated the efficacy of 64Cu-intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab as an adjuvant treatment after pancreatic cancer surgery using an orthotopic xenografted mouse model. Methods: Efficacy of adjuvant 64Cu-ipRIT was investigated in a human pancreatic cancer mouse model harboring orthotopic xenografts of XPA-1DC cells. To reproduce clinical situation, pancreatic cancer xenograft was surgically resected at the point when primary tumors were visible in the pancreas, but obvious metastatic lesions were not yet apparent. Tumor development were observed with the aid of a stereoscopic fluorescence microscope. The dose-effect relationship in toxicity for intraperitoneally injected 64Cu- cetuximab was examined to determine therapeutic dose. For adjuvant 64Cu-ipRIT, 22.2 MBq 64Cu-cetuximab was injected intraperitoneally into mice one day after surgery and the survival was compared to the surgery-only control. For comparison, adjuvant chemotherapy with gemcitabine was also examined using the same model. Results: We established a mouse model that developed not only primary tumors in the pancreas but also subsequently reproduced local recurrence, hepatic metastasis, and peritoneal dissemination after surgery like pancreatic cancer patients. Adjuvant 64Cu-ipRIT with 64Cu-labeled cetuximab after surgery showed significant improvement of survival compared to surgery only control and effectively suppressed local recurrence, hepatic metastasis, and peritoneal dissemination with little toxicity in this model. Adjuvant chemotherapy with gemcitabine nominally prolonged the survival but the effect was not statistically significant. Conclusion: 64Cu-ipRIT with cetuximab can be an effective adjuvant therapy after pancreatic cancer surgery.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": " The  Society of Nuclear Medicine and Molecular Imaging(SNMMI) annual meeting 2019", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yoshii, Yukie"}], "nameIdentifiers": [{"nameIdentifier": "765065", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Hiroki"}], "nameIdentifiers": [{"nameIdentifier": "765066", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshimoto, Mitsuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "765067", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ming-Rong, Zhang"}], "nameIdentifiers": [{"nameIdentifier": "765068", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagatsu, Kotaro"}], "nameIdentifiers": [{"nameIdentifier": "765069", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugyo, Aya"}], "nameIdentifiers": [{"nameIdentifier": "765070", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "765071", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Tatsuya"}], "nameIdentifiers": [{"nameIdentifier": "765072", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshii, Yukie", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765073", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Hiroki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765074", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshimoto, Mitsuyoshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765075", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ming-Rong, Zhang", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765076", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagatsu, Kotaro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765077", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugyo, Aya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765078", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Atsushi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765079", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Tatsuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "765080", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/76134", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-06-27"}, "publish_date": "2019-06-27", "publish_status": "0", "recid": "76134", "relation": {}, "relation_version_is_last": true, "title": ["Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode"], "weko_shared_id": -1}
  1. 学会発表・講演等
  2. 口頭発表

Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode

https://repo.qst.go.jp/records/76134
https://repo.qst.go.jp/records/76134
bdea9d13-236e-4a81-9502-f4b6c25d828f
Item type 会議発表用資料 / Presentation(1)
公開日 2019-06-27
タイトル
タイトル Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_c94f
資源タイプ conference object
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 Yoshii, Yukie

× Yoshii, Yukie

WEKO 765065

Yoshii, Yukie

Search repository
Matsumoto, Hiroki

× Matsumoto, Hiroki

WEKO 765066

Matsumoto, Hiroki

Search repository
Yoshimoto, Mitsuyoshi

× Yoshimoto, Mitsuyoshi

WEKO 765067

Yoshimoto, Mitsuyoshi

Search repository
Ming-Rong, Zhang

× Ming-Rong, Zhang

WEKO 765068

Ming-Rong, Zhang

Search repository
Nagatsu, Kotaro

× Nagatsu, Kotaro

WEKO 765069

Nagatsu, Kotaro

Search repository
Sugyo, Aya

× Sugyo, Aya

WEKO 765070

Sugyo, Aya

Search repository
Tsuji, Atsushi

× Tsuji, Atsushi

WEKO 765071

Tsuji, Atsushi

Search repository
Higashi, Tatsuya

× Higashi, Tatsuya

WEKO 765072

Higashi, Tatsuya

Search repository
Yoshii, Yukie

× Yoshii, Yukie

WEKO 765073

en Yoshii, Yukie

Search repository
Matsumoto, Hiroki

× Matsumoto, Hiroki

WEKO 765074

en Matsumoto, Hiroki

Search repository
Yoshimoto, Mitsuyoshi

× Yoshimoto, Mitsuyoshi

WEKO 765075

en Yoshimoto, Mitsuyoshi

Search repository
Ming-Rong, Zhang

× Ming-Rong, Zhang

WEKO 765076

en Ming-Rong, Zhang

Search repository
Nagatsu, Kotaro

× Nagatsu, Kotaro

WEKO 765077

en Nagatsu, Kotaro

Search repository
Sugyo, Aya

× Sugyo, Aya

WEKO 765078

en Sugyo, Aya

Search repository
Tsuji, Atsushi

× Tsuji, Atsushi

WEKO 765079

en Tsuji, Atsushi

Search repository
Higashi, Tatsuya

× Higashi, Tatsuya

WEKO 765080

en Higashi, Tatsuya

Search repository
抄録
内容記述タイプ Abstract
内容記述 Objectives: Pancreatic cancer has a very poor prognosis. Surgery is the primary treatment for patients with resectable pancreatic cancer; however, local recurrence, hepatic metastasis, and peritoneal dissemination often occur even after extensive surgery. Adjuvant chemotherapy, typically with gemcitabine, has been used clinically, but with a modest survival benefit. To achieve a better outcome, we investigated the efficacy of 64Cu-intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab as an adjuvant treatment after pancreatic cancer surgery using an orthotopic xenografted mouse model. Methods: Efficacy of adjuvant 64Cu-ipRIT was investigated in a human pancreatic cancer mouse model harboring orthotopic xenografts of XPA-1DC cells. To reproduce clinical situation, pancreatic cancer xenograft was surgically resected at the point when primary tumors were visible in the pancreas, but obvious metastatic lesions were not yet apparent. Tumor development were observed with the aid of a stereoscopic fluorescence microscope. The dose-effect relationship in toxicity for intraperitoneally injected 64Cu- cetuximab was examined to determine therapeutic dose. For adjuvant 64Cu-ipRIT, 22.2 MBq 64Cu-cetuximab was injected intraperitoneally into mice one day after surgery and the survival was compared to the surgery-only control. For comparison, adjuvant chemotherapy with gemcitabine was also examined using the same model. Results: We established a mouse model that developed not only primary tumors in the pancreas but also subsequently reproduced local recurrence, hepatic metastasis, and peritoneal dissemination after surgery like pancreatic cancer patients. Adjuvant 64Cu-ipRIT with 64Cu-labeled cetuximab after surgery showed significant improvement of survival compared to surgery only control and effectively suppressed local recurrence, hepatic metastasis, and peritoneal dissemination with little toxicity in this model. Adjuvant chemotherapy with gemcitabine nominally prolonged the survival but the effect was not statistically significant. Conclusion: 64Cu-ipRIT with cetuximab can be an effective adjuvant therapy after pancreatic cancer surgery.
会議概要(会議名, 開催地, 会期, 主催者等)
内容記述タイプ Other
内容記述 The Society of Nuclear Medicine and Molecular Imaging(SNMMI) annual meeting 2019
発表年月日
日付 2019-06-24
日付タイプ Issued
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 18:51:42.478791
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3